Jaclyn P. Lyman - Concepedia

Author

Jaclyn P. Lyman

Memorial Sloan Kettering Cancer Center

Also Known As

Cho, Soonweng, Jaclyn Lyman, Jaclyn P Lyman, Jaclyn P. Lyman, Jaclyn Paige Lyman, Lyman, Jaclyn

Publications

Citations

H-Index

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center Dana-Farber Cancer Institute The University of Texas MD Anderson Cancer Center University of California, San Francisco Bristol-Myers Squibb (United States)

About

Jaclyn P. Lyman is an author at Memorial Sloan Kettering Cancer Center specializing in cancer therapeutics, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	771
2	Immunology	4	4	390
3	Pathology	4	4	420
4	Pharmacology	3	3	104
5	Health Sciences	1	1	23

Jaclyn P. Lyman

Publications

Citations

H-Index

Page 1

	Year	Citations
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial Lacey Padrón, Deena M. Maurer, Mark H. O’Hara, Nature Medicine Randomized Phase 2Pancreatic CancerGastrointestinal OncologyMedicineImmunologic Analyses	2022	316
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study Mark H. O’Hara, Eileen M. O’Reilly, Gauri R. Varadhachary, The Lancet Oncology Phase 1BPancreatic CancerMetastatic Pancreatic AdenocarcinomaMedicineImmunology	2020	286
Novel Methylated Biomarkers and a Robust Assay to Detect Circulating Tumor DNA in Metastatic Breast Cancer Mary Jo Fackler, Zoila A. Lopez‐Bujanda, Christopher B. Umbricht, Cancer Research	2014	158
Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013 Tari A. King, Jaclyn P. Lyman, Mithat Gönen, Journal of Clinical Oncology	2016	82
A prospective analysis of surgery and survival in stage IV breast cancer (TBCRC 013). Tari A. King, Jaclyn P. Lyman, Mithat Gönen, Journal of Clinical Oncology Surgical OncologyBreast OncologyCancer ManagementPrognosisTbcrc 013	2016	65
Abstract CT004: A Phase Ib study of CD40 agonistic monoclonal antibody APX005M together with gemcitabine (Gem) and nab-paclitaxel (NP) with or without nivolumab (Nivo) in untreated metastatic ductal pancreatic adenocarcinoma (PDAC) patients Mark H. O’Hara, Eileen M. O’Reilly, Rosemarie Mick, Cancer Research ImmunologyPathologyImmunotherapeuticsPharmacotherapyImmunotherapy	2019	65
Gemcitabine (Gem) and nab-paclitaxel (NP) ± nivolumab (nivo) ± CD40 agonistic monoclonal antibody APX005M (sotigalimab), in patients (Pts) with untreated metastatic pancreatic adenocarcinoma (mPDAC): Phase (Ph) 2 final results. Mark H. O’Hara, Eileen M. O’Reilly, Robert A. Wolff, Journal of Clinical Oncology ImmunodeficienciesImmunologyPathologyPharmacotherapyUntreated Mpdac	2021	23
Abstract CT004: A Phase Ib study of CD40 agonistic monoclonal antibody APX005M together with gemcitabine (Gem) and nab-paclitaxel (NP) with or without nivolumab (Nivo) in untreated metastatic ductal pancreatic adenocarcinoma (PDAC) patients Mark H. O’Hara, Eileen M. O’Reilly, Rosemarie Mick, Clinical Trials ImmunologyPathologyImmunotherapeuticsPharmacotherapyImmunotherapy	2019	16

Page 1